Quantitative Imaging of Tumor-Associated Macrophages and Their Response to Therapy Using 64Cu-Labeled Macrin.
暂无分享,去创建一个
Miles A. Miller | R. Weissleder | C. Rodell | M. Pittet | Ran Li | M. Nahrendorf | Rainer H. Kohler | Hye-Yeong Kim | T. Ng | G. Courties | Mark Prytyskach
[1] R. Advani,et al. Magnetic Resonance Imaging of Tumor-Associated Macrophages: Clinical Translation , 2018, Clinical Cancer Research.
[2] Michael F. Cuccarese,et al. TLR7/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy , 2018, Nature Biomedical Engineering.
[3] R. Weinberg,et al. Understanding the tumor immune microenvironment (TIME) for effective therapy , 2018, Nature Medicine.
[4] Steven J. M. Jones,et al. The Immune Landscape of Cancer , 2018, Immunity.
[5] R. Weissleder,et al. Imaging the emergence and natural progression of spontaneous autoimmune diabetes , 2017, Proceedings of the National Academy of Sciences.
[6] Miles A. Miller,et al. Prediction of Anti-cancer Nanotherapy Efficacy by Imaging , 2017, Nanotheranostics.
[7] Miles A. Miller,et al. Radiation therapy primes tumors for nanotherapeutic delivery via macrophage-mediated vascular bursts , 2017, Science Translational Medicine.
[8] Heather H Gustafson,et al. Progress in tumor-associated macrophage (TAM)-targeted therapeutics. , 2017, Advanced drug delivery reviews.
[9] Miles A. Miller,et al. In vivo imaging reveals a tumor-associated macrophage–mediated resistance pathway in anti–PD-1 therapy , 2017, Science Translational Medicine.
[10] R. Keep,et al. CD163 Expression in Neurons After Experimental Intracerebral Hemorrhage , 2017, Stroke.
[11] Karen Campbell,et al. 64Cu-MM-302 Positron Emission Tomography Quantifies Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in Patients with Metastatic Breast Cancer , 2017, Clinical Cancer Research.
[12] A. Mills,et al. Tumor-associated macrophage expression of PD-L1 in implants of high grade serous ovarian carcinoma: A comparison of matched primary and metastatic tumors. , 2017, Gynecologic oncology.
[13] Ralph Weissleder,et al. Heterogeneity of macrophage infiltration and therapeutic response in lung carcinoma revealed by 3D organ imaging , 2017, Nature Communications.
[14] R. Korn,et al. Correlation between Ferumoxytol Uptake in Tumor Lesions by MRI and Response to Nanoliposomal Irinotecan in Patients with Advanced Solid Tumors: A Pilot Study , 2017, Clinical Cancer Research.
[15] Hsiao-Ying Wey,et al. Polyglucose nanoparticles with renal elimination and macrophage avidity facilitate PET imaging in ischaemic heart disease , 2017, Nature Communications.
[16] D. Ling,et al. Improved Tumor Uptake by Optimizing Liposome Based RES Blockade Strategy , 2017, Theranostics.
[17] P. Kantoff,et al. Cancer nanomedicine: progress, challenges and opportunities , 2016, Nature Reviews Cancer.
[18] Ian D. McGilvray,et al. Mechanism of hard nanomaterial clearance by the liver , 2016, Nature materials.
[19] M. Pittet,et al. The role of myeloid cells in cancer therapies , 2016, Nature Reviews Cancer.
[20] Kathryn J Fowler,et al. Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial. , 2016, The Lancet. Oncology.
[21] A. J. Tavares,et al. Analysis of nanoparticle delivery to tumours , 2016 .
[22] Jedd D. Wolchok,et al. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations , 2016, Science Translational Medicine.
[23] Glen J Weiss,et al. Phase I Study of PSMA-Targeted Docetaxel-Containing Nanoparticle BIND-014 in Patients with Advanced Solid Tumors , 2016, Clinical Cancer Research.
[24] R. Weissleder,et al. Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy. , 2016, Immunity.
[25] Ashley M. Laughney,et al. Predicting therapeutic nanomedicine efficacy using a companion magnetic resonance imaging nanoparticle , 2015, Science Translational Medicine.
[26] Ralph Weissleder,et al. Tumour-associated macrophages act as a slow-release reservoir of nano-therapeutic Pt(IV) pro-drug , 2015, Nature Communications.
[27] Zahi A. Fayad,et al. PET Imaging of Tumor-Associated Macrophages with 89Zr-Labeled High-Density Lipoprotein Nanoparticles , 2015, The Journal of Nuclear Medicine.
[28] Q. Ye,et al. A New Approach to Reduce Toxicities and to Improve Bioavailabilities of Platinum-Containing Anti-Cancer Nanodrugs , 2015, Scientific Reports.
[29] G. von Heijne,et al. Tissue-based map of the human proteome , 2015, Science.
[30] Jan Grimm,et al. Nanoparticles for imaging: top or flop? , 2014, Radiology.
[31] Jeffrey W Pollard,et al. Tumor-associated macrophages: from mechanisms to therapy. , 2014, Immunity.
[32] Miles A. Miller,et al. Platinum Compounds for High‐Resolution In Vivo Cancer Imaging , 2014, ChemMedChem.
[33] R. Weissleder,et al. Imaging macrophages with nanoparticles. , 2014, Nature materials.
[34] K. Schäkel,et al. Low-dose irradiation programs macrophage differentiation to an iNOS⁺/M1 phenotype that orchestrates effective T cell immunotherapy. , 2013, Cancer cell.
[35] Christina S. Leslie,et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression , 2013, Nature Medicine.
[36] P. Libby,et al. Nanoparticle PET-CT Detects Rejection and Immunomodulation in Cardiac Allografts , 2013, Circulation. Cardiovascular imaging.
[37] James E Bear,et al. Nanoparticle clearance is governed by Th1/Th2 immunity and strain background. , 2013, The Journal of clinical investigation.
[38] F. Yeh,et al. Decreased reticuloendothelial system clearance and increased blood half-life and immune cell labeling for nano- and micron-sized superparamagnetic iron-oxide particles upon pre-treatment with Intralipid. , 2013, Biochimica et biophysica acta.
[39] R. Jain,et al. Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. , 2013, Cancer research.
[40] Ralph Weissleder,et al. Polymeric Nanoparticle PET/MR Imaging Allows Macrophage Detection in Atherosclerotic Plaques , 2013, Circulation research.
[41] M. Zucchetti,et al. Role of macrophage targeting in the antitumor activity of trabectedin. , 2013, Cancer cell.
[42] H. Maeda,et al. The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. , 2013, Advanced drug delivery reviews.
[43] Stuart S Berr,et al. PET imaging of tumor associated macrophages using mannose coated 64Cu liposomes. , 2012, Biomaterials.
[44] R. Weissleder,et al. 89Zr-labeled dextran nanoparticles allow in vivo macrophage imaging. , 2011, Bioconjugate chemistry.
[45] M. Uesaka,et al. Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size. , 2011, Nature nanotechnology.
[46] Daniel G. Anderson,et al. Therapeutic siRNA silencing in inflammatory monocytes , 2011, Nature Biotechnology.
[47] Srikanth K. Iyer,et al. Multimodal silica nanoparticles are effective cancer-targeted probes in a model of human melanoma. , 2011, The Journal of clinical investigation.
[48] Masahiro Fujita,et al. Comparison of [11C]-(R)-PK 11195 and [11C]PBR28, two radioligands for translocator protein (18 kDa) in human and monkey: Implications for positron emission tomographic imaging of this inflammation biomarker , 2010, NeuroImage.
[49] Xiao-Feng Sun,et al. Expression of the macrophage antigen CD163 in rectal cancer cells is associated with early local recurrence and reduced survival time , 2009, International journal of cancer.
[50] T. Jacks,et al. Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase , 2009, Nature Protocols.
[51] D. Koller,et al. The Immunological Genome Project: networks of gene expression in immune cells , 2008, Nature Immunology.
[52] O. Stål,et al. Breast cancer expression of CD163, a macrophage scavenger receptor, is related to early distant recurrence and reduced patient survival , 2008, International journal of cancer.
[53] M. Rehli,et al. Expression of CD68 in Non‐Myeloid Cell Types , 2008, Scandinavian journal of immunology.
[54] Y. Imai,et al. Antibodies to CD11b, CD68, and lectin label neutrophils rather than microglia in traumatic and ischemic brain lesions , 2007, Journal of neuroscience research.
[55] Olli Yli-Harja,et al. Software for quantification of labeled bacteria from digital microscope images by automated image analysis. , 2005, BioTechniques.
[56] Tae-You Kim,et al. Phase I and Pharmacokinetic Study of Genexol-PM, a Cremophor-Free, Polymeric Micelle-Formulated Paclitaxel, in Patients with Advanced Malignancies , 2004, Clinical Cancer Research.
[57] A. Giatromanolaki,et al. Liposomal doxorubicin and conventionally fractionated radiotherapy in the treatment of locally advanced non-small-cell lung cancer and head and neck cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[58] E. Andreeva,et al. Subendothelial smooth muscle cells of human aorta express macrophage antigen in situ and in vitro. , 1997, Atherosclerosis.
[59] S. Lee,et al. Quantitative analysis of total macrophage content in adult mouse tissues. Immunochemical studies with monoclonal antibody F4/80 , 1985, The Journal of experimental medicine.
[60] F. Hefti. High-performance size-exclusion chromatography: a buffer for the reliable determination of molecular weights of proteins. , 1982, Analytical biochemistry.
[61] S. Snyder,et al. An improved 2,4,6-trinitrobenzenesulfonic acid method for the determination of amines. , 1975, Analytical biochemistry.
[62] F. Smith,et al. COLORIMETRIC METHOD FOR DETER-MINATION OF SUGAR AND RELATED SUBSTANCE , 1956 .